P1036b (10044): Directly Observed Therapy in HIV-Infected Adolescents

Study Status Study Restriction

Concluded

United States

What is P1036b?

P1036b was a pilot study of directly observed therapy (DOT) among adolescents.  The study was designed to examine the feasibility of providing DOT to HIV-1 infected adolescents, to assess subject satisfaction of the DOT intervention model developed in PACTG P1036a and to evaluate the cost, reproducibility, and impact on adherence of the model.

Study documents:

Sites where the study is implemented:

CRS ID Site Name City Country
Site Selection in progress.

Study contacts:

Study Chair: Aditya Gaur

Study Vice-Chair: Marvin Belzer

Study Vice-Chair: Patricia Flynn

Investigator: George McSherry

Laboratory Data Manager (LDM): Heather Sprenger

Laboratory Technologist: William Kabat

Medical Officer: Bill Kapogiannis

Medical Officer: Karin Klingman

Neuropsychologist: Patricia Garvie

Pharmacologist: Francesca Aweeka

Protocol Pharmacist: Lynette Purdue

Statistician: Paula Britto

Statistician: Hu Chengcheng

Virologist: Stephen Spector

Westat Representative: Jennifer Bryant

CTS: IMPAACT.OperationsCenter@fstrf.org

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.